möglich sobald bei der ZB eingereicht worden ist.
Nanoparticle-mediated siRNA delivery in human epithelial lung cells cultured at the air-liquid interface.
In: RNA Therapeutics. Berlin [u.a.]: Springer, 2025. 417-437 (Methods Mol. Biol. ; 2965)
The approval of ONPATTRO® in 2018 resembled a milestone for small interfering RNA (siRNA) therapies, introducing the first siRNA lipid nanoparticle (LNP) into clinical use. This breakthrough has improved research efforts in siRNA-based therapeutics. Similarly, benefits like scalability and adaptability have led to enormous research also in polymeric siRNA delivery systems, leading to polyplexes or micelleplexes after complexation. However, extrahepatic delivery, such as pulmonary administration of these therapies, remains poorly understood and is under active investigation. To enable high-throughput screening while following the 3R principles and minimizing in vivo studies, advanced cell culture systems like the air-liquid interface (ALI) model are being developed. ALI cell culture replicates key physiological features of the lung, including mucus and surfactant production, tight junction formation, and the establishment of a pseudostratified monolayer. These properties make ALI models highly suitable for sophisticated in vitro studies of pulmonary delivery systems. This chapter provides a comprehensive overview of ALI models, including their establishment, cultivation, microscopy-based characterization, and applications in evaluating nanoparticle uptake and gene knockdown efficiency using polymeric nanoparticles and LNPs.
Altmetric
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern
Publikationstyp
Artikel: Sammelbandbeitrag/Buchkapitel
Schlagwörter
Air–liquid Interface ; In Vitro ; Lipid Nanoparticles ; Nanoparticles ; Polyplexes ; Pulmonary Delivery ; Sirna
Sprache
englisch
Veröffentlichungsjahr
2025
HGF-Berichtsjahr
2025
ISSN (print) / ISBN
1064-3745
e-ISSN
1940-6029
Bandtitel
RNA Therapeutics
Zeitschrift
Methods in Molecular Biology
Quellenangaben
Band: 2965,
Seiten: 417-437
Verlag
Springer
Verlagsort
Berlin [u.a.]
Begutachtungsstatus
Peer reviewed
Institut(e)
Institute of Lung Health and Immunity (LHI)
POF Topic(s)
30202 - Environmental Health
Forschungsfeld(er)
Lung Research
PSP-Element(e)
G-501600-014
PubMed ID
40877518
Erfassungsdatum
2025-11-04